Profilo
Raymond Kaempfer was the founder of Atox Bio Ltd., which was founded in 2003, where he held the title of Chief Scientific Officer from 2003 to 2011.
He is currently a Member of the European Molecular Biology Organization.
Dr. Kaempfer's former positions include being a Faculty Member at Harvard University and a Professor of Molecular Biology & Cancer Research at The Hebrew University of Jerusalem.
Dr. Kaempfer received a doctorate degree from the Massachusetts Institute of Technology.
Posizioni attive di Raymond Kaempfer
| Società | Posizione | Inizio |
|---|---|---|
European Molecular Biology Organization | Corporate Officer/Principal | - |
Precedenti posizioni note di Raymond Kaempfer
| Società | Posizione | Fine |
|---|---|---|
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Fondatore | - |
Formazione di Raymond Kaempfer
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
European Molecular Biology Organization | |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Health Technology |
















